| |DECEMBER 20248INDIAN PHARMA FIRMS ATTRACTS 5,260 CRORE INVESTMENT, FUELS 12,490 NEW JOBSLIPELLA CONCLUDES PHASE 2A DOSING FOR LP-310 IN ORAL LICHEN PLANUSIndian pharmaceutical firms have pledged to invest more than Rs 5,260 crore, with the goal of generating 12,490 job openings within the pharmaceutical industry. The Telangana government has announced that six well-known pharmaceutical companies, such as Dr Reddy's Laboratories, Aurobindo Pharma, and Hetero Labs, have agreed to establish facilities in the Pharma City near here by signing memorandums of understanding (MoUs).The companies' representatives held discussions with Chief Minister A Revanth Reddy and Industries Minister D Sridhar Babu at the Secretariat to complete the agreements."The pharma company managements signed MoUs to establish the industries. The six companies expressed their interest to invest more than Rs 5260 crore. The investments will provide 12,490 job opportunities in the pharma sector. The government will allocate land for the establishment of the new pharma manufacturing units in the recognised pharma city," the release said.As per the MoUs, MSN Laboratories will create a manufacturing unit and an R&D center, Laurus Labs and Aurobindo Pharma will establish individual formulation units, and Gland Pharma will open an R&D center as well as injectables and drug substance manufacturing units.Dr. Reddy's Labs plans to construct a unit for injectable and biosimilars, while Hetero Labs will set up a manufacturing plant for finished dose and injectables, according to the announcement. The Chief Minister directed officials to assign land for the new amenities and guarantee that the essential infrastructure is in place at Pharma City, with construction set to commence in the next four months. POLipella Pharmaceuticals Inc has reported the conclusion of dosing for the initial group in its multi-center phase 2a clinical trial for LP-310, a liposomal-tacrolimus oral rinse intended for treating oral lichen planus (OLP). In the initial group, eight participants were given 0.25 mg of LP-310, showing encouraging early outcomes. There were no serious adverse events reported related to the product. Pharmacokinetic information showed that all patients had very low or unmeasurable whole blood tacrolimus levels, indicating that LP-310 could offer targeted treatment with limited impact on the entire body. Moreover, none of the patients experienced any major side effects while taking LP-310.Janet Okonski, director of clinical operations at Lipella Pharmaceuticals, noted feedback from the study site, stating, "The tolerability observed in this initial cohort is a promising indicator. Oral lichen planus severely affects patient quality of life, and an effective, well-tolerated treatment is desperately needed. It's encouraging to see this kind of response at an early stage.""We are proud of this milestone and are grateful to our investigators and study staff for their dedication and hard work," said Dr. Michael Chancellor, chief medical officer of Lipella Pharmaceuticals. "Our commitment to developing a safe and effective therapy for oral lichen planus patients remains steadfast as we activate additional sites and begin enrolling the next dose cohort. The pace of our progress has been promising, and we are on track to deliver top-line data by year-end and complete the trial by mid-2025."POTOP STORIES
< Page 7 | Page 9 >